Cellectis Stock

Cellectis Equity

Delisted·Jun 19, 2026

The The Equity of Cellectis (ALCLS.PA) as of Jul 28, 2026 is 131.03 M USD. In the previous year, The Equity was 84.70 M USD — a change of 54.71% (higher).

Equity

131.03 MUSD

YoY

54.71%

Last updated:

In 2026, Cellectis's equity was 131.03 M USD, a 54.71% increase from the 84.70 M USD equity in the previous year.

Access this data via the Eulerpool API

Cellectis Stock analysis

What does Cellectis do? Cellectis SA is an emerging biotechnology company focused on developing innovative therapies for cancer and other serious diseases. It was founded in 1999 by a French scientist named André Choulika and is headquartered in Paris, France. Cellectis' main business is the development of CAR-T cell therapies, which involve reprogramming immune cells to target specific types of cancer. This method specifically targets cancer cells while leaving healthy cells unaffected, offering a more precise and less invasive alternative to traditional cancer treatments. Cellectis' business model is centered around developing tailored cancer treatments for individual patients using its Cellectis System, a combination of genomic and cellular technologies. The company also has subsidiaries and joint ventures focusing on different segments of the biopharmaceutical market, such as Calyxt, which specializes in genetic modification of crops, and Ectycell, which focuses on developing cell therapies for rare blood diseases. Cellectis offers a range of products and services focused on cancer drug development, including cell therapies, genetic testing, clinical trials, and consulting services. Its products and services are tailored to the individual needs of patients and aim to revolutionize cancer treatment through advanced technology and innovative approaches. In summary, Cellectis is an innovative biotechnology company successfully focusing on developing tailored cancer therapies. With its wide range of products and services catering to patient needs, and with advancements in cancer therapy, Cellectis is well positioned to become a key player in the biopharmaceutical industry. Cellectis is one of the most popular companies on Eulerpool.

Equity Details

Analyzing Cellectis's Equity

Cellectis's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Cellectis's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Cellectis's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Cellectis's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Cellectis’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Cellectis stock

The Equity of Cellectis is 131.03 M USD in 2026.

Access this data via the Eulerpool API

Balance Sheet — Cellectis

All Key Metrics — Cellectis